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in Hematopoietic Cell Transplantation for Primary
Immune Deficiency
Brandon M. Triplett,1,4 Chong Wang,2 Jie Yang,2 Mari Dallas,1,4 Christine Hartford,1
Vanessa Howard,3 Asha Pillai,1,4 David Shook,1,4 Ashok Srinivasan,1,4 Joseph Laver,1,4
Wing Leung1,4This study analyzes the hematopoietic cell transplantation experience in patients with immune deficiency at
a single institution. The objective is to comprehensively evaluate the short-term and long-term outcomes
with various preparative regimens, donor grafts, and ex vivo manipulations to identify transplantation ap-
proaches that most likely favor early donor immune competency without generating excessive toxicity. Clin-
ical outcomes were evaluated in 52 consecutive patients with immune deficiencies. Thirty-seven of the 52
patients (71%) survived with attenuation of their underlying disease. The use of a melphalan-based re-
duced-intensity conditioning preparative regimen and immunomagnetic CD31 T cell depletion techniques
(when T cell depletion was indicated) were associated with improved event-free survival. Survivors who
received a preparative regimen other than a melphalan-based reduced-intensity regimen suffered from
therapy-related morbidities or chronic/recurrent infections. Our findings indicate that melphalan-based re-
duced-intensity conditioning regimens and immunomagnetic CD31 T cell depletion limit therapy-related
toxicity, and demonstrate promising results for the early establishment of donor immune competency.
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Since the earliest hematopoietic cell transplanta-
tions (HCT) performed more than 40 years ago,
HCT has been a curative option for several primary
immune deficiencies, including severe combined im-
mune deficiency (SCID) and Wiskott-Aldrich syn-
drome (WAS) [1,2]. Although gene therapy is
a promising future alternative, HCT remains the
therapy of choice for the majority of patients [3,4].
However, despite decades of experience with
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oi.org/10.1016/j.bbmt.2012.07.014successful transplantation continue to evolve with
time, and remain controversial.
The history of HCT for SCID illustrates this evo-
lution. It is particularly successful in patients with
SCID, with .80% long-term survival when an HLA-
matched sibling donor is available [5]. Evenwhen alter-
native donors are required, the majority of recipients
survive [5-7]. The success of HCT in patients with
SCID is due in large part to a significantly reduced
immune barrier, allowing minimal or no conditioning
before transplantation [6]. Although the earliest
HCTs for SCID typically used conventional myeloa-
blative techniques, it became clear that avoiding
myeloablative conditioning regimens was desirable to
reduce transplantation-related mortality. The prefer-
ence then shifted toward performing even mismatched
donor HCT in patients with SCID who received
conditioning without chemotherapy or radiation ther-
apy after this type of HCT was found to be well toler-
ated and largely successful [6]. However, recent results
indicate that the lack of myeloablation can lead to
incomplete long-term donor immune reconstitution
and untoward clinical outcomes [8-10].Whenmyeloa-
blative preparative regimens are used, complete
replacement of the defective immune system is more
readily achieved [8], but at a cost of possibly increased1911
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This has led many institutions, including ours, to
use reduced-intensity conditioning (RIC) regimens
to minimize toxicity and deliver fully competent
long-term donor engraftment. Although RIC regi-
mens may deliver reduced toxicity, many current
RIC regimens fail to achieve fully competent long-
term donor immune reconstitution [8,12,13].
In contrast to SCID, other immune deficiencies,
such asWAS, have a significant host immunologic bar-
rier to overcome. They do, however, share the same
desired outcome of minimal toxicity with long-term
donor immunocompetency [14]. Here we describe
the experience with allogeneic HCT for immune
deficiencies at a single institution, evaluating both
short-term and long-term outcomes for the evolving
therapies in this patient population, and identify
potential strategies for future patients.PATIENTS AND METHODS
Patients
This study was a retrospective analysis of all HCTs
performed in patients with immune deficiency be-
tween 1991 and 2010 at St. Jude Children’s Research
Hospital. A written protocol was submitted to, and
approval was obtained from, St. Jude’s Institutional
Review Board before the initiation of research activi-
ties. Data were collected and analyzed in anonymized
fashion, in accordance with the rules and regulations
of the Health Information Portability and Account-
ability Act and the Institutional Review Board.
Fifty-nine consecutive patients were identified. Six
patients with X-linked agammaglobulinemia who
received a sibling graft with no conditioning were
described previously [15] and were excluded from the
present analysis. One patient who underwent a first
HCT at an outside institution was also excluded, leav-
ing 52 patients, who received a total of 70 HCTs, for
analysis. This cohort includes 23 patients with SCID,
10 with WAS, 9 with familial hemophagocytic lym-
phohistiocytosis (HLH), 4 with X-linked lymphopro-
liferative syndrome (XLP), 2 with CD40-ligand
deficiency (CD40L), 1 with immunodysregulation
polyendocrinopathy enteropathy X-linked syndrome
(IPEX), 1 with leukocyte adhesion deficiency (LAD)
type 1, 1 with chronic granulomatous disease, and 1
with Chediak-Higashi syndrome (CHS). Twenty-five
patients received their initial transplants from parental
donors (18 matched at 3 of 6 loci, 6 matched at 4 of 6
loci, and 1 a phenotypic 6 of 6 match), 16 patients
received their initial transplants from matched unre-
lated donors (3 matched at 5 of 6 loci and 13 matched
at a minimum of 6 of 6 loci), and 11 patients received
their initial transplants from genotypically matched
sibling donors (Table 1).Methods
All patients were housed in high-efficiency par-
ticulate air–filtered rooms on an HCT unit during
the peritransplantation period. Standard supportive
care guidelines were followed for all patients and
typically included pneumocystis prophylaxis with
trimethoprim-sulfamethoxazol, antifungal prophylaxis
with an azole or echinocandin, and anti-herpes simplex
virus and cytomegalovirus (CMV) prophylaxis with
acyclovir. Weekly monitoring for Epstein-Barr virus
(EBV), CMV, and adenovirus by quantitative PCR
and for aspergillosis by galactamanin assay was insti-
tuted in 2002. Before 2000, all parental donor recipi-
ents received marrow grafts (n 5 10); later recipients
received peripheral blood stem cells (PBSCs)
(n 5 15). All sibling and unrelated donor transplant
recipients received marrow grafts, except 2 unrelated
donor transplant recipients with WAS who received
PBSCs.
All 25 primary parental grafts were T cell depleted
(TCD). Seven of 16 unrelated grafts, and none of the
11 sibling grafts, were TCD. Before 2001, grafts
were rendered TCD by complement mediated lysis
with either CD3 or CD6/CD8 antibodies (comple-
ment/Ab) (n 5 16). Before 2001, grafts were rendered
TCD using the CliniMACS device (n 5 16) initially
via CD341 cell selection (n 5 5) and later via CD31
cell depletion (n 5 11). Median CD31 cell doses for
TCD grafts were 1.02  106/kg for complement/Ab,
0.01  106/kg for CliniMACS CD341 selection, and
0.01  106/kg for CliniMACS CD31 depletion, com-
pared with 33.11  106/kg for unmanipulated grafts.
Median CD341 cell doses for TCD grafts were
2.77  106/kg for complement/Ab, 41.59  106/kg
for CliniMACS CD341 selection, and 27.74  106/kg
for CliniMACS CD31 depletion, compared with
7.24  106/kg for unmanipulated grafts.
Through 2005, preparative regimens were primar-
ily myeloablative (busulfan or total body irradiation
[TBI]) or used no chemotherapy or radiotherapy.
Five patients received a TBI dose of 1200 cGy, with
1140 cGy given to 1 patient and 1400 cGy given to 1
patient. Busulfan dosing was i.v. and targeted in one-
half of the patients (12 of 24), with the rest receiving
oral dosing. Dosing was myeloablative in all busulfan
recipients, with a median cumulative busulfan dose
of 16 mg/kg. Between 2006 and 2010, 10 of 13 patients
received melphalan-based RIC (#140 mg/m2).
The choices of T cell depletion technique and
conditioning regimen were based on the protocol
available or physician discretion. An HLA-matched
sibling was the preferred donor for all patients when
available. An HLA-matched unrelated donor was the
second choice for non-SCID recipients. Parental do-
nors were used in non-SCID recipients only when
nomatched (related or unrelated) donor was available,
Table 1. Patients
Total (n 5 52) SCID (n 5 23) WAS (n 5 10) HLH (n 5 9) Other (n 5 10)
Age, years, median (range) 0.8 (0.0-18.9) 0.5 (0.0-0.9) 4.7 (1.5-10.9) 1.3 (0.5-4.1) 8.6 (0.7-18.9)
Donor type, n (%)
Parent 25 (48) 19 (83) 2 (20) 3 (33) 1 (10)
Sibling 11 (21) 4 (17) 2 (20) 2 (22) 3 (30)
Unrelated 16 (31) 0 (0) 6 (60) 4 (44) 6 (60)
Preparative regimen, n (%)
Myeloablative 31 (60) 9 (39) 8 (80) 8 (89) 6 (60)
Bu + Cy-based 22 9 4 4 5
Flu + Bu-based 2 2
TBI + Cy-based 7 4 2 1
Reduced intensity 10 (19) 3 (13) 2 (20) 1 (11) 4 (40)
Flu + Mel-based 9 2 2 1 4
Mel 1 1
No chemotherapy 11 (21) 11 (48) 0 (0) 0 (0) 0 (0)
Cyclosporine, n (%)
No 25 (48) 17 (74) 2 (20) 3 (33) 3 (30)
Yes 27 (52) 6 (26) 8 (80) 6 (67) 7 (70)
Anti–T cell antibody, n (%)
No 23 (44) 16 (70) 1 (10) 3 (33) 3 (30)
Yes 29 (56) 7 (30) 9 (90) 6 (67) 7 (70)
TCD, n (%)
Antibody/complement 16 (31) 10 (43) 4 (40) 2 (22) 0 (0)
CliniMACS 16 (31) 9 (39) 2 (20) 3 (33) 2 (20)
None 20 (38) 4 (17) 4 (40) 4 (44) 8 (80)
HLA match status (n of 6), n (%)
3 18 (35) 13 (57) 1 (10) 3 (33) 1 (10)
4 6 (12) 5 (22) 1 (10) 0 (0) 0 (0)
5 3 (6) 0 (0) 3 (30) 0 (0) 0 (0)
6 25 (48) 5 (22) 5 (50) 6 (67) 9 (90)
Maximum acute GVHD grade, n (%)
0 36 (69) 20 (87) 5 (50) 5 (56) 6 (60)
I 7 (13) 2 (9) 2 (20) 2 (22) 1 (10)
II 5 (10) 1 (4) 1 (10) 1 (11) 2 (20)
III 3 (6) 0 (0) 2 (20) 1 (11) 0 (0)
IV 1 (2) 0 (0) 0 (0) 0 (0) 1 (10)
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matched sibling donor.
Before 2000, donor chimerism was determined by
fluorescent in situ hybridization analysis, available
predominantly in bone marrow specimens in sex-
mismatched patients. Later, donor chimerism was
always available, predominantly in peripheral blood
samples, using variable number tandem repeat analy-
sis. Lineage-specific chimerism was not performed
routinely.
Statistical Analysis
The evaluated clinical outcomes included overall
survival (OS) and event-free survival (EFS). OSwas de-
fined as the time from the date of first HCT to death
from any cause, and EFS was defined as the time
from the date of first HCT to the occurrence of death
from any cause or graft failure. Graft failure was
defined as\5% donor chimerism or failure of donor
immune reconstitution necessitating a second HCT.
The decision to proceed to a second HCT was made
jointly by immunology and transplant clinicians. Pa-
tients who were still alive without experiencing an
event at their last follow-up date were considered cen-
sored in survival estimates.OS and EFS distributions were estimated by the
Kaplan-Meier method [16] and compared using the
exact log-rank test [17]. The Fisher exact test, c2
test, and Kruskal-Wallis test were used to compare
categorical variables across groups. P\ .05 was the
nominal significance level. SAS version 9.2 (SAS Insti-
tute, Cary, NC) and StatXact Windows version 8 (Cy-
tel, Cambridge, MA) were used for statistical analysis.RESULTS
SCID
All 23 patients with SCID received a related donor
graft (Table 1). Four patients received a sibling graft;
all were alive and clinically well at last follow-up.
The remaining 19 patients received a parental graft.
Three of these patients died within 90 days of first
HCT, and 2 others died shortly after a second HCT.
Four of the 5 patients who died succumbed to docu-
mented invasive infection (2 with aspergillosis, 1 with
CMV, and 1 with respiratory syncytial virus), and
1 died of rapid pulmonary failure (no organism identi-
fied) (Table 2). Fourteen patients survived a median of
7.5 years after parental donor HCT, for a 6-year OS of
Table 2. Snapshot of Clinical Outcomes
UPN Donor Preparation
Died,
Day
Alive,
Age, Years
Disease
Type
Disease
Phenotype Outcome Summary
SCID patients
1 Sibling BuCy 12.0 RAG B2NK+ Clinically well; no medications
2 Sibling BuCy 15.3 AR NA Clinically well; playing soccer, good in school
3 Sibling Mel 2.2 RAG B2NK+ Clinically well; off IVIG, getting vaccinations
4 Sibling No 0.2 AR B+NK+ Lost to follow-up on return to home institution
5 Haploidentical BuCy 15.7 XL B+NK2 On augmentin, Zithromax, IVIG; chronic
cough and chronic stable bronchiectasis
6 Haploidentical BuCy 20 ADA B2NK2 MOF, Aspergillosis
7 Haploidentical BuCy 13.0 XL B+NK2 Well, in school; mild intermittent asthma
8 Haploidentical BuCy 11.4 XL B+NK2 Well, in school; hypothyroid on
synthroid, osteoporosis
9 Haploidentical BuCy 10.7 RAG B2NK+ Well, in school; on SQIG and Septra, chronic
neutropenia and thrombocytopenia
10 Haploidentical BuCy 18.2 XL NA Chronic warts, chronic cough;
smokes, noncompliant with augmentin
11 Haploidentical BuCy 3.4 CHHS NA Clinically well, in school; dwarfed
owing to cartilage-hair hypoplasia syndrome
12 Haploidentical No 24 NA B+NK2 ARDS, biopsy showed interstitial
necrotizing alveolitis, cultures negative
13 Haploidentical No 13.6 XL B+NK2 Clinically well; recurrent warts, on IVIG and Bactrim
14 Haploidentical No 1097 ADA B2NK2 Aspergillosis, ARDS, acute renal failure
15 Haploidentical No 7.9 gc B+NK2 Post-HCT RSV; now clinically well, limited skin
chronic GVHD, on Bactrim and IVIG
16 Haploidentical No 7.0 gc B+NK2 Clinically well; intermittent sinopulmonary
infections, on IVIG and Bactrim
17 Haploidentical No* 6.4 NA NA In school; nephogenic diapetes insipidus, juvenile
rheumatoid arthritis on methotrexate, on Bactrim
18 Haploidentical No 1.9 ADA B2NK2 Tracheostomy due to pre-HCT
pseudomonas, on SQIG and Bactrim
19 Haploidentical No 240 CD3d B+NK+ ARDS, pulmonary failure, RSV pneumonitis,
adenovirus in blood and stool
20 Haploidentical No 86 AR B2NK+ ARDS, CMV pneumonitis, Pseudomonas sepsis
21 Haploidentical No* 3.6 ADA B2NK2 On ADA replacement, CMV reactivation
now resolved, on IVIG and Bactrim
22 Haploidentical FluMel 1.2 IL7R B+NK+ Mycobacterium infection of hand
resolved; growing and developing
23 Haploidentical FluMel 1.2 IL7R B+NK+ Well; growing and developing appropriately
WAS patients
24 Sibling BuCy 8.5 Bacillus cereus bacteremia, fungus on scan; now clinically well, HTN on lisinipril
25 Sibling BuCy 15.2 Preparing for college; chronic GVHD skin, on Cellcept, topical tacrolimus,
Bactrim, and penVK
26 Unrelated BuCy 7.3 Coagulase-negative Staphylococcus bacteremia; now clinically well
27 Unrelated BuCy 84 MOF, CMV, EBV, and adenovirus in blood
28 Unrelated TBI 152 EBV PTLD, CMV in blood, ARDS, pulmonary failure, Staphylococcus aureus bacteremia
29 Unrelated TBI 11.0 Clinically well; swimming and surfing, wrestling
30 Unrelated TBI 10.0 Post-HCT cellulitis, urinary tract infection; now attention deficit hyperactivity disorder,
on Synthroid, penVK postsplenectomy
31 Unrelated TBI 250 Enterococcus, S aureus, Candida in blood, pulmonary Aspergillosis, EBV PTLD
32 Haploidentical FluMel 4.3 Post-HCT Clostridium difficile, CMV and EBV reactivation; now clinically well,
no medications
33 Haploidentical FluMel 4.2 Post-HCT RSV, S aureus bacteremia; now clinically well, myringotomy tubes now out
HLH patients
34 Sibling TBI 12.1 Short stature, osteochondrma
35 Sibling BuCY 38 Hepatic VOD, MOF
36 Unrelated BuCY 13.5 On GH and Synthroid; hypertension, HTN on amlodipine, renal insufficiency on
erythropoietin, ovarian failure on estrogen
37 Unrelated BuCY 7.0 Post-HCT EBV reactivation, systemic inflammatory response syndrome;
now feels well, rapid puberty, on Lupron
38 Unrelated BuCY 6.0 Intubated for respiratory insufficiency; now feels well, metabolic syndrome,
no medications
39 Unrelated TBI 9.1 Feels well; good in school, on GH and Sythroid, cataract removal, osteochondroma
40 Haploidentical FluBu 226 Adenoviral pneumonia, Aspergillosis
41 Haploidentical FluBu 28 Progressive EBV
42 Haploidentical FluMel 76 Bowel perforation, MOF, Enterococcus, Pseudomonas, Aspergillosis, parainfluenza.
XLP patients
43 Unrelated BuCY 5.5 Early Pseudomonas sepsis, CMV, BK virus; now worked up for depression,
intermittent sinusitis
44 Unrelated FluMel 2.5 Burkitt lymphoma and short gut pre-HCT, EBV reactivation post-HCT resolved;
otherwise well
(Continued )
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Table 2. (Continued )
UPN Donor Preparation
Died,
Day
Alive,
Age, Years
Disease
Type
Disease
Phenotype Outcome Summary
45 Unrelated TBI 182 Interstitial pneumonitis, respiratory failure, EBV
46 Haploidentical BuCY 41 Hepatic VOD, MOF, adenovirus
Other patients
47 Sibling BuCy 9.6 40L Clinically well, only medication is Synthroid
48 Sibling BuCy 4.0 40L GVHD resolved, active; mild osteoporosis and hypercholersterolemia
49 Sibling BuCY 13.0 CHS Neurocognitive difficulty; insulin resistance syndrome, on metformin
50 Unrelated FluMel 2.0 LAD1 EBV reactivation, LAD corrected; clinically well, DLI-induced limited
skin GVHD resolved
51 Unrelated FluMel 2.6 CGD Post-HCT EBV reactivation, seizure; now well, in school, mild
osteoporosis improving
52 Unrelated FluMel 3.6 IPEX Early S aureus bacteremia, adenoviral and C difficile colitis;
now no problems
40L indicates CD40 ligand deficiency; ADA, adenosine deaminase deficiency; AR, autosomal recessive; ARDS, acute respiratory distress syndrome;
CD3d, CD3d deficiency; CDG, chronic granulomatous disease; FluMel, fludarabine + melphalan-based regimen; gc, common g-chain deficiency;
GH, growth hormone; HTN, hypertension; IL7R, interleukin-7 receptor deficiency; mel, melphalan + campath only; MOF, multiorgan failure; NA,
not available; PTLD, posttransplantation lymphoproliferative disorder; RAG, RAG deficiency; RSV, respiratory syncytial virus; sibling, matched sibling
donor; SQIG, s.c. immune globulin; TBI, total body irradiation + cyclophosphamide-based regimen; unrelated, matched unrelated donor; VOD,
veno-occlusive disease; XL, X-linked.
*Campath alone.
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SCID patients was 76% 6 11%. The small number
of patients precludes subset analysis, but of note, 7 of
7 X-linked SCID recipients survived.
Falling donor chimerism and overt graft failure
was a significant problem for early parental donor re-
cipients regardless of whether they received busulfan
plus cyclophosphamide (BuCy) or no conditioning.
Only 3 of the first 17 recipients achieved donor en-
graftment without the need for subsequent HCT.
Three patients died in the early posttransplantation
period, 1 patient had no donor chimerism and was
maintained on enzyme replacement, and the 10 re-
maining recipients received a total of 26 HCTs. A ma-
jority of subsequent transplants were from the previous
donor without conditioning, but 9 of the 10 patients
who underwent subsequent HCT received condition-
ing with at least 1 of their transplants. Eight of these 10
patients survived long-term.
The 2 most recent parental donor recipients re-
ceived a melphalan-based RIC regimen with fludara-
bine and alemtuzumab. Both patients received
maternal PBSC grafts that had been rendered TCD
by CliniMACS CD31 depletion and received low-
dose donor lymphocyte infusion (DLI; 0.05  106
CD31 cells/kg) electively at 12 weeks posttransplanta-
tion before returning home. At the time of this report,
both patients are well and maintain full donor T cell
chimerism.
None of the 17 SCID survivors followed at our in-
stitution achieved full donor chimerism (Table 3). All
3 sibling recipients are i.v. immunoglobulin (IVIG)-
independent. However, 7 of 14 parental donor recipi-
ents remain on IVIG replacement, including 2 of 6
patients conditioned with BuCy and 5 of 6 patients
who initially received no conditioning. Although thefew sibling recipients are uniformly well, long-term
antibiotic use is necessary inmost parental donor recip-
ients, who are susceptible to intermittent and chronic
infections (Table 2).WAS
Two patients with WAS received a sibling graft, 6
received an unrelated graft, and 2 received a parental
donor graft (Table 1). Seven of the 10 patients survive,
at a median of 8.7 years post-HCT (Table 2). All 6 un-
related donor transplant recipients received myeloa-
blative conditioning. Two developed grade III
GVHD and subsequently died of infectious etiologies.
Both were age.8 years at the time of HCT, and both
received a TCD unrelated donor graft with a TBI-
based preparative regimen. Another patient died dur-
ing the first year with viral infection.
Both sibling donor transplant recipients received
BuCy conditioning and currently survive. One devel-
oped grade II acute GVHD but is clinically well more
than 15 years post-HCT despite some continued lim-
ited skin chronic GVHD. The 2 patients with WAS
who received a parental donor HCT have survived
more than 4 years post-HCT. They received condi-
tioning with fludarabine, thiotepa, melphalan, and
OKT3.The graftswereCD31TCDwithCliniMACS.
Both patients are clinically well with full donor
chimerism, noGVHD, and no IVIG replacement ther-
apy (Table 3). One patient has a low level of IgA, but
normal IgG and IgM levels. Both patients have docu-
mented protective titers to polio, hepatitis B, mumps,
and diphtheria after vaccination (Supplemental
Table). Currently, 6 of 7 WAS survivors have full
donor chimerism, and none have developed autoim-
mune disease.
Table 3. Immune Reconstitution in Survivors at Last Follow-Up
UPN Donor Conditioning TCD Year
HCT,
n
Chimerism
(Donor) IVIG IgG IgM IgA
Lymphocytes,  106/uL
Total CD3+ CD3+CD4+ CD3+CD8+ CD56+ CD19+
SCID Survivors
1 Sibling BuCy No 12.0 1 NA Off 1334 69 276 1600 1020 570 390 340 40
2 Sibling BuCy No 15.3 1 NA Off 721 254 106 NA
3 Sibling Mel No 2.2 1 27% Off 770 128 41 1500 1100 390 530 350 50
5 Haploidentical BuCy Ab 15.7 1 B cell; 2% Still on 882 28 <4 800 780 150 580 <10 20
7 Haploidentical BuCy Ab 13.0 2 NA Off 1066 122 98 3500 2770 1230 1470 210 560
8 Haploidentical BuCy Ab 11.4 2 NA Off 868 120 235 1600 1410 560 720 80 110
9 Haploidentical BuCy Ab 10.7 3 23% Still on 726 30 74 400 330 240 90 60 10
10 Haploidentical BuCy Ab 18.2 2 B cell; 1% Off 304 60 23 1100 1050 460 610 30 20
11 Haploidentical BuCy Ab 3.4 3 52% Off 873 104 193 NA
13 Haploidentical No Ab 13.6 4 NA Still on 951 44 119 2800 2520 980 1230 80 20
15 Haploidentical No 34 7.9 2 38% Still on 881 26 <4 2900 2730 1100 1560 30 140
16 Haploidentical No 3 7.0 1 16% Still on 497 40 11 2600 2440 600 1270 <10 160
17 Haploidentical No* 3 6.4 3 20% Off 1006 55 39 700 480 270 180 150 70
18 Haploidentical No 3 1.9 1 37% Still on 854 28 34 2200 1970 1250 440 60 110
21 Haploidentical No* 3 3.6 1 Absent Still on 905 84 37 1500 820 80 680 630 110
22 Haploidentical FluMel 3 1.2 1 45% Off 694 70 8 2900 2090 1330 730 410 410
23 Haploidentical FluMel 3 1.2 1 35% Off 490 44 <4 1200 980 720 230 70 160
WAS survivors
24 Sibling BuCy No 8.5 1 Full Off 845 66 87 1600 980 580 300 110 500
25 Sibling BuCy No 15.2 1 Full Off 919 35 119 1300 960 530 390 220 120
26 Unrelated BuCy No 7.3 1 Full Off 930 52 113 1300 1110 590 420 80 120
29 Unrelated TBI Ab 11.0 1 Full Off 478 18 54 2700 2130 1110 890 140 460
30 Unrelated TBI Ab 10.0 1 44% Off 1290 53 11 4000 3280 1560 1440 200 560
32 Haploidentical FluMel 3 4.3 1 Full Off 1287 193 <4 2600 1920 960 730 340 360
33 Haploidentical FluMel 3 4.2 1 Full Off 834 58 97 3100 2600 1640 650 90 370
HLH survivors
34 Sibling TBI No 12.1 1 Full Off 691 43 62 2800 2160 1090 840 340 360
36 Unrelated BuCy Ab 13.5 2 Full Off 742 44 123 2300 1820 1080 600 140 370
37 Unrelated BuCy No 7.0 1 Full Off 823 82 159 2300 1730 780 760 300 250
38 Unrelated BuCy No 6.0 1 Full Off 1033 42 168 1700 1290 700 530 190 240
39 Unrelated TBI Ab 9.1 1 Full Off 740 83 123 2200 1890 900 860 180 150
Others
43 XLP Unrelated BuCy No 5.5 1 Full Off 851 142 142 2600 1950 880 810 160 520
44 XLP Unrelated FluMel No 2.5 1 Full Off 549 40 <4 1200 900 520 290 170 120
47 40L Sibling BuCy No 9.6 1 Full Off 1016 173 121 4500 3740 2340 1170 180 630
48 40L Sibling BuCy No 4.0 1 Full Off 1020 113 115 1500 1140 500 590 150 210
49 CHS Sibling BuCy No 13.0 1 82% Off 957 166 98 2900 2040 1290 620 200 590
50 LAD Unrelated FluMel No 2.0 1 Full Off 648 65 <4 4600 3400 1840 1240 180 1060
51 CGD Unrelated FluMel No 2.6 1 Full Off 436 30 47 2600 2030 1300 570 340 230
52 IPEX Unrelated FluMel 3 3.6 1 21% Off 484 54 50 1700 1390 780 580 70 260
3 indicates CliniMACS CD3+ depletion; 34, CliniMACS CD34+ selection; 40L, CD40 ligand deficiency; Ab, complement/antibody; CGD, chronic gran-
ulomatous disease; FluMel, fludarabine +melphalan-based regimen; mel, melphalan + campath only; NA, not available; sibling, matched sibling donor; TBI,
total body irradiation + cyclophosphamide-based regimen; unrelated, matched unrelated donor.
Values in bold type were below the normal range for current age. Lymphocyte subsets were quantified by multiplying the absolute lymphocyte counts to
the percentage of cells labeled in each category by multicolor flow cytometry. Normal values for the lymphocyte subsets were determined by testing 57
healthy children age >12 months at our institution.
*Campath alone.
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Of the 9 patients with familial HLH, 4 received an
unrelated donor graft, 2 received a sibling donor graft,
and 3 received a parental donor graft (Table 1). All 6
patients with HLA-matched donors received myeloa-
blative conditioning. One sibling donor recipient
developed grade III GVHD and veno-occlusive dis-
ease of the liver and died at day 38 of multiorgan fail-
ure. The 5 remaining patients survive, at a median of
9.1 years post-HCT (Table 2). One of the unrelated
donor survivors underwent a second unrelated donor
HCT 8 months after the first HCT owing to disease
recurrence. All survivors demonstrate full donor chi-merism and complete immune reconstitution, with
documented vaccine response, normal Ig levels, and
IVIG independence (Table 3). All survivors also have
evidence of endocrinopathy, ranging from obesity
alone to hypothyroidism, short stature, and ovarian
failure (Table 2).
All 3 haploidentical donor recipients died. All
received fludarabine-based conditioning (2 with busul-
fan, 1 with melphalan) and grafts rendered TCD by
CD341 enrichment. All required DLI post-HCT for
active infections, and 1 also underwent a second hap-
loidentical donor HCT. However, all 3 recipients
died with active infections.
Figure 1. OS in all patients (A), by disease category (P 5 .53) (B), and
by donor source (P 5 .28) (C).
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The 10 remaining recipients included 4 with XLP,
2 with CD40L, 1 with IPEX, 1 with CHS, 1 with
chronic granulomatous disease, and 1 with LAD.
One patient with XLP who received TBI-based mye-
loablative conditioning and an unrelated donor graft
died at day 182 post-HCT, and 1 patient with XLP
who received BuCy-based myeloablative condition-
ing and a haploidentical donor graft died at day 41,
both with invasive viral infections. Another patient
with XLP currently survives 5.5 years after unrelated
donor HCT with BuCy-based conditioning despite
the development of grade IV acute GVHD. Both pa-
tients with CD40L and the patients with CHS have
survived 4-13 years after sibling donor HCT with
BuCy-based conditioning. The 4 remaining patients
received fludarabine and melphalan RIC with unre-lated donor grafts; all are clinically well, including
the IPEX patient with mixed donor chimerism
(Tables 2 and 3).Group Analysis
Thirty-eight of 52 patients (73%) are currently
alive, at a median of 7.7 years post-HCT. Fourteen pa-
tients died, at a median of 85 days after primary HCT
(range, 20-1097 days). Invasive infection was a docu-
mented contributor in 12 of these 14 deaths
(Table 2). Estimated OS was 75% 6 6% at 1 year
post-HCT and 72% 6 8% at 6 years post-HCT
(Figure 1A). Survival was not statistically different
among patients with different diagnoses (P 5 .53)
(Figure 1B). The 6-year OS was 91%6 10% in sibling
donor recipients, 75% 6 13% in unrelated donor
recipients, and 63% 6 12% in parental donor recipi-
ents (P 5 .28) (Figure 1C).
Fifteen patients failed to achieve durable donor en-
graftment with their first HCT. Fourteen patients un-
derwent a subsequent HCT, and 1 patient was
managed with supportive care and enzyme replace-
ment. EFS was used to estimate the probability of sur-
vival after achieving durable donor T cell engraftment
with the firstHCT.Patientswho received amelphalan-
based preparative regimen had a better EFS than those
who received another preparative regimen (P 5 .035)
(Figure 2A). The use of TCD grafts was associated
with a worse EFS (P 5 .008) (Figure 2B); however,
among the patients who received a TCD graft, EFS
was significantly higher in those who received a Clini-
MACS CD31 TCD graft compared with those who
received a graft rendered TCD by CliniMACS
CD341 selection or complement/antibody methods
(P5 .012) (Figure 2C).
Only 8 patients (16%) developed grade II-IV acute
GVHD after the first HCT, and 1 additional patient
developed grade II GVHD after a second (with an un-
manipulated parental graft) HCT. Despite the fact
that the majority of TCD grafts were HLA-
mismatched, only 3 of 32 (9%) TCD graft recipients
developed grade II-IV acute GVHD. Conversely, 5
of 20 (25%) T cell–replete graft recipients developed
grade II-IV acuteGVHD afterHCT.Of note, all 4 pa-
tients who developed grade III-IV GVHD received
myeloablative conditioning, 3 of whomwere unrelated
donor transplant recipients. Five of the 9 patients who
developed grade II-IV GVHD died, compared with 9
of 38 patients with grade 0 or I GVHD (P 5 .1019).
Five patients developed chronic GVHD, of which 2
were extensive. Three patients had complete resolu-
tion, 1 patient remains on topical therapy only, and 1
patient remains on mycophenolate and topical therapy
with limited skin involvement. None of the 11 patients
who received a CliniMACS CD31 TCD graft devel-
oped grade II-IV acute GVHD or chronic GVHD.
Table 4. Patients with Transplantation-Related Morbidity at
Last Follow-Up, by Conditioning Regimen
Complications Bu/TBI Melphelan None
Survive without transplantation-related
morbidity, n (%)
6 (19) 8 (80) 1 (9)
Survive with therapy-related morbidity, n (%)* 11 (35) 1 (10) 0
Endrocrine 9 0 0
Osteoporosis 2 1 0
Hypertension 2 0 0
Survive with immune-related morbidity, n (%)† 5 (16) 0 6 (55)
Chronic antibiotics 4 0 6
Chronic infection/warts 3 0 2
Deceased 9 (29) 1 (10) 4 (36)
*Therapy-related morbidity includes organ dysfunction associated with
chemotherapy or radiotherapy given during the conditioning regimen,
including endocrinopathy.
†Immune-related morbidity refers to complications from incomplete
immunocompetency, such as chronic infections or the need for prophy-
lactic antibiotics.
Figure 2. EFS by conditioning (P 5 .035) (A), TCD versus T cell re-
plete (P 5 .008) (B), and by T cell depletion method (P 5 .012) (C).
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normal daily activities (Table 2). However, medical
problems related to the HCT procedure or to incom-
plete immune competency are frequent (Table 4).
Eleven of 22 survivors who received a busulfan-based
or TBI-based conditioning regimen are afflicted by
endocrinopathies and other related toxicities. Six of 7
survivors who received no preparative chemotherapy
for primary HCT are afflicted with chronic infections
and require ongoing IVIG and antibiotic support. In
all, only 7 of 29 survivors who did not receive amelpha-
lan-based RIC are free of any current transplantation-
or disease-related medical problems at last follow-up.
Conversely, 8 of 9 survivors who received a melpha-
lan-based RIC regimen are currently without medical
problems (Tables 2 and 4).DISCUSSION
Allogeneic HCT remains the primary therapeutic
option for the majority of patients with immune defi-
ciency; however, the optimal transplantation ap-
proaches remain undefined [18]. Over the last
20 years, HCT for patients with immune deficiency
at our institution has been largely successful, in that
a majority of the patients survive and experience atten-
uation of their underlying disease regardless of disease
type, donor source, or conditioning regimen. Mortal-
ity in this population is overwhelmingly related to in-
vasive infections in the early posttransplantation
period, emphasizing the need for rapid reconstitution
of immune competency.
It is postulated that some degree of myeloid en-
graftment is required for long-term donor immune
competency [8]. Our present findings provide strong
support for the requirement of some level of pretrans-
plantation myeloablation, even in patients with a sig-
nificantly decreased immune barrier, such as those
with SCID. However, full myeloablation was associ-
ated with significant therapy-related morbidity in
survivors, given that both busulfan and TBI are asso-
ciated with a number of therapy-related long-term
morbidities, including endocrinopathies and second
cancers [19-21]. It must be noted that one-half of our
busulfan recipients received nontargeted oral dosing,
which could have led to inappropriately high or low
levels of exposure in those recipeints and thus may
have predisposed them to worse outcome. Given this
increased morbidity and the fact that RIC regimens
are safe and effective in immunodeficient patients
[22], the use of melphalan-based RIC has become in-
stitutional practice in recent years. The 10 patients
who received melphalan-based RIC at our institution
demonstrated an improved toxicity profile compared
with their historical counterparts. Importantly, all sur-
vivors are currently free of the requirement for IVIG
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postulate that this is related to full T cell engraftment
and improved mixed myeloid and B cell chimerism [8],
although lineage-specific chimerism was not routinely
obtained in our patients. Certainly, patients who re-
ceived melphalan-based RIC had a better EFS com-
pared with the patients receiving other preparative
regimens in our cohort (P5 .035), indicating that sus-
tained donor T cell engraftment was consistently ob-
tained in this group. Other factors, however, such as
improved supportive care and infection surveillance
in recent years, might have contributed to the im-
proved EFS.
Consistent with published literature, we found that
when HLA-matched sibling donors are available, out-
comes are particularly good regardless of underlying
immune deficiency [5,6,14,23,24]. In addition, the
sibling donor recipients have a uniformly good long-
term clinical course. Unfortunately, a sibling donor
was available for only a minority of recipients. The
use of alternative donors, although effective in amajor-
ity of patients, is associated with worse outcomes
compared with sibling donor transplants in immuno-
deficient recipients [5,6,14,23,24].
AnHLA-matched unrelated donor is often consid-
ered when an appropriate sibling donor is not avail-
able. However, because many patients with immune
deficiency present with illness and multiple active in-
fections, they often are unable to wait the approxi-
mately 4 months [25] necessary to procure an
unrelated donor graft (if available). Unrelated umbili-
cal cord blood offers a rapidly available alternative do-
nor source [26,27]; however, with these transplants,
post-HCTdonor lymphocytes are not available should
the patient develop serious viral infection or a serious
drop in donor chimerism.
Parental donors have the benefit of being rapidly
available for virtually all patients, both before and after
HCT. However, parental grafts typically require ex-
tensive T cell depletion, owing to the degree of HLA
mismatch [28]. The rate of GVHD appeared to be
lower in our TCD graft recipients, despite the fact
that this group contained the preponderance of
HLA-mismatched graft recipients. This indicates
that T cell depletion is successful in controlling
GVHD.However, the combination of T cell depletion
and HLA mismatch begets delayed and often incom-
plete immune reconstitution, particularly if no condi-
tioning is used [29]. As seen in malignant diseases [30],
newer T cell depletion techniques, such as immuno-
magnetic CD31 cell depletion, seemed to improve do-
nor engraftment and immune reconstitution in our
parental donor recipients; their improved EFS indi-
cated that they were more likely to survive and achieve
successful donor engraftment without needing a subse-
quent HCT. Similar to other immunomagnetic T cell
depletion techniques, CD31 cell depletion allows foran extensively TCD graft with a large hematopoietic
stem cell dose; however, it also preserves important
facilitator cells and innate immune cells, such as natu-
ral killer cells.
In conclusion, the majority of the immunodefi-
cient patients who underwent HCT in our institution
over the past 2 decades achieved cure of disease and
currently participate in normal daily activities, regard-
less of their underlying disease and donor source.
However, many survivors who received full myeloabla-
tion or no conditioning are burdened with either long-
term toxicities or chronic infections. Melphalan-based
RIC regimens were associated with less short-term and
potentially less long-term toxicities in our patients.
Immunomagnetic CD31 T cell depletion of mis-
matched grafts is effective in GVHD prevention, and
also was associated with better EFS compared
with complement/Ab-mediated depletion or CD341
enrichment. Therefore, the use of melphalan-based
RIC regimens seems to safely provide sufficient mye-
loablation, which, together with efficient ex-vivo
CD31 T cell depletion techniques, can safely achieve
reliable donor immune reconstitution for patients
with a variety of immune deficiencies. Future investi-
gations of this transplantation platform in larger co-
horts of patients are warranted to validate the
findings reported herein and to further evaluate
long-term donor immune competency.ACKNOWLEDGMENTS
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